> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Zimmer Biomet Now Sees Autonomous Monogram Robot In First Half Of 2027, Not 2028
- URL: https://www.bullished.co/zimmer-biomet-now-sees-autonomous-monogram-robot-in-first-half-of-2027-not-2028-44636ab3/
- Published: 2026-11-04T15:28:31.000Z
- Updated: 2026-11-04T15:28:31.000Z
- Description: The orthopedic device maker raised its 2026 outlook, but U.S. knee sales fell 2% in the third quarter.
- Author: Matteo Parrino
- Tags: Earnings, ZBH, Industry: Healthcare

[Zimmer Biomet](https://www.bullished.co/tag/zbh/), which makes knee and hip replacements, sports medicine products and surgical robots, now anticipates it can launch a surgeon-guided, fully autonomous version of its Monogram robot in the first half of 2027, CEO Ivan Tornos said on the company's third-quarter earnings call Wednesday. The original expectation was 2028, and Tornos said the company will file the robot's FDA application "very, very soon," while also raising its [2026 earnings guidance](https://finance.yahoo.com/markets/stocks/articles/zimmer-q3-earnings-snapshot-113604170.html?ref=bullished.co).

## Monogram's pitch to surgeons

Tornos said the company expects to file Monogram's 510(k) application, the FDA clearance request, significantly ahead of schedule. Pressed by a UBS analyst on go-to-market strategy, he said the clinical trial produced "zero patient safety reports" and that bone cutting takes less than three minutes.

He said roughly 80% of U.S. surgeons do not use a robot, a figure he put close to 90% outside the country. Monogram will be shown to surgeons at the American Association of Hip and Knee Surgeons meeting in Dallas this week.

Tornos was careful about the regulatory step. "We got to get an approval first," he told a Truist analyst, adding that "filing a 510K does not mean an approval." He would not size Monogram's 2027 impact or commit to a quarter when knee growth improves, saying only that knees should perform better at some point.

## Knees still falling

Knee sales fell 2.6% in constant currency in the third quarter, with U.S. knees down 2%. Tornos tied the U.S. result to the sales force transition and a highly competitive implant market, and said China pressure weighed on international knees.

Total net sales were $2.63 billion, up 3.1% as reported and 3.7% in constant currency. Hips grew 7%, and technology and data grew 13%.

The company raised 2026 organic constant-currency sales growth guidance to 3% to 3.5%, from 2.25% to 3.25%. Adjusted earnings per share guidance moved to $8.50 to $8.60, from $8.47 to $8.59\. Shares traded at $109.15 in Wednesday trading, up about 12% from the prior close of $97.06.

## Sales force overhaul at the midpoint

Zimmer is three quarters into an eight-quarter move to dedicated specialist sales reps in the U.S., with over 75% now fully dedicated, Tornos said. He said the process is ahead of expectations, and that benefits take 12 to 18 months to appear. He called the third of three stages the riskiest, and the company is early in it.

On costs, he said operating expenses run at 46% of sales, which "leaves room for dramatic improvement" through manufacturing consolidation and AI work with outside partners. A multi-year distribution deal with Think Surgical for the T-Mini robot sits alongside Monogram in the company's knee push.

The company plans to give 2027 guidance in early 2027, Tornos said.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat Estimates](https://finance.yahoo.com/healthcare/articles/zimmer-biomet-zbh-q3-earnings-113502755.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Zimmer: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/zimmer-q3-earnings-snapshot-113604170.html?ref=bullished.co) — Associated Press
- [Zimmer Biomet Non-GAAP EPS of $1.90 beats by $0.02, revenue of $2.06B beats by $20M, r | Seeking Alpha](https://seekingalpha.com/news/4664577-zimmer-biomet-non-gaap-eps-of-190-beats-by-002-revenue-of-206b-beats-by-20m-raises-fy-guidance?ref=bullished.co) — seekingalpha.com
- [Zimmer: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/zimmer-q3-earnings-snapshot/616-735b1b37-06ea-425a-8785-f07a992aee86?ref=bullished.co) — Associated Press
- [Zimmer: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/zimmer-q3-earnings-snapshot/616-735b1b37-06ea-425a-8785-f07a992aee86?ref=bullished.co) — Associated Press

### More on Zimmer Biomet

- [Zimmer Biomet Shares Jump 13%, Adding $2.5 Billion After Company Lifts 2026 Sales Forecast](https://www.bullished.co/zimmer-biomet-shares-jump-13-adding-2-5-billion-after-company-lifts-2026-sales-forecast-aeb7a127/)
- [Zimmer Biomet Lifts 2026 Organic Sales Outlook To 3.0%-3.5% As Knee Sales Fall 2.6%](https://www.bullished.co/zimmer-biomet-lifts-2026-organic-sales-outlook-to-3-0-3-5-as-knee-sales-fall-2-6-77f888f9/)

[All Zimmer Biomet (ZBH) coverage →](https://www.bullished.co/tag/zbh/)